Heilongjiang ZBD Pharmaceutical Co Ltd Market Cap ($689.31 Million)
Market Cap & Net Worth: Heilongjiang ZBD Pharmaceutical Co Ltd (603567)
Heilongjiang ZBD Pharmaceutical Co Ltd market cap. Heilongjiang ZBD Pharmaceutical Co Ltd (SHG:603567) has a market capitalization of $689.31 Million (CN¥4.71 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #10294 globally and #2721 in its home market, demonstrating a 8.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Heilongjiang ZBD Pharmaceutical Co Ltd's stock price CN¥5.01 by its total outstanding shares 940235287 (940.24 Million). Also see Heilongjiang ZBD Pharmaceutical Co Ltd (603567) cash flow conversion for how efficiently the company converts equity into cash flow.
Heilongjiang ZBD Pharmaceutical Co Ltd Market Cap History (2015–2026)
Heilongjiang ZBD Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows change from $3.26 Billion to $689.31 Million (-11.50% CAGR). Check current stock price of Heilongjiang ZBD Pharmaceutical Co Ltd for real-time trading data and today's change.
Heilongjiang ZBD Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Heilongjiang ZBD Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Heilongjiang ZBD Pharmaceutical Co Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.54x
Heilongjiang ZBD Pharmaceutical Co Ltd's market cap is 1.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.55 Billion | $2.39 Billion | $509.56 Million | 1.06x | 5.00x |
| 2017 | $1.84 Billion | $3.14 Billion | $520.87 Million | 0.59x | 3.53x |
| 2018 | $1.58 Billion | $2.78 Billion | $462.44 Million | 0.57x | 3.42x |
| 2019 | $1.70 Billion | $3.29 Billion | $408.65 Million | 0.52x | 4.17x |
| 2020 | $1.52 Billion | $3.40 Billion | $436.29 Million | 0.45x | 3.48x |
| 2021 | $2.08 Billion | $4.13 Billion | $332.10 Million | 0.50x | 6.27x |
| 2022 | $1.75 Billion | $4.21 Billion | $185.44 Million | 0.42x | 9.44x |
| 2023 | $1.67 Billion | $3.14 Billion | $472.74 Million | 0.53x | 3.54x |
| 2024 | $1.60 Billion | $2.70 Billion | $438.22 Million | 0.59x | 3.64x |
| 2025 | $1.23 Billion | $798.06 Million | -$1.37 Billion | 1.54x | N/A |
Competitor Companies of 603567 by Market Capitalization
Companies near Heilongjiang ZBD Pharmaceutical Co Ltd in the global market cap rankings as of November 8, 2026. Also see total assets of Heilongjiang ZBD Pharmaceutical Co Ltd for a full breakdown of the balance sheet.
Key companies related to Heilongjiang ZBD Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Heilongjiang ZBD Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Heilongjiang ZBD Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Heilongjiang ZBD Pharmaceutical Co Ltd's market cap moved from $3.26 Billion to $ 689.31 Million, with a yearly change of -11.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥689.31 Million | -43.90% |
| 2025 | CN¥1.23 Billion | -23.02% |
| 2024 | CN¥1.60 Billion | -4.61% |
| 2023 | CN¥1.67 Billion | -4.46% |
| 2022 | CN¥1.75 Billion | -15.90% |
| 2021 | CN¥2.08 Billion | +37.10% |
| 2020 | CN¥1.52 Billion | -10.82% |
| 2019 | CN¥1.70 Billion | +7.76% |
| 2018 | CN¥1.58 Billion | -14.15% |
| 2017 | CN¥1.84 Billion | -27.70% |
| 2016 | CN¥2.55 Billion | -22.00% |
| 2015 | CN¥3.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Heilongjiang ZBD Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $689.31 Million USD |
| MoneyControl | $689.31 Million USD |
| MarketWatch | $689.31 Million USD |
| marketcap.company | $689.31 Million USD |
| Reuters | $689.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the pharmaceuticals business in China. The company researches, develops, produces, and sale traditional Chinese medicine preparations, biological agents, and chemical agents, as well as involved in the pharmaceutical and Chinese medicinal materials trade; and leasing business. It also engages in pharmaceutical manufacturing; contract manufactur… Read more